Exchange trial for patients with multiple sclerosis
We are currently enrolling in the EXCHANGE trial (Exploring the safety and tolerability of conversion to dose-titrated Oral Siponimod in patients with advancing forms of relapsing multiple sclerosis: A 6-month open label, multi-center Phase IIIb study).
This is a trial for patients with multiple sclerosis. The study is looking at how well patients tolerate changing medication for multiple sclerosis from their current medication to an investigational drug called siponimod. The information learned in the study will help doctors understand if and when they should switch patients from their current MS medications to siponimod, as well as how safe and tolerable this is for patients.
You may qualify if:
- You are 18-65 years old
- You have advancing RMS (relapsing multiple sclerosis)
- You have been continuously treated with beta-interferons, glatiramer acetate, fingolimod, dimethyl fumarate, or teriflunomide for at least 3 months at the time of consent
* The study staff will review your medications with you to determine if you are eligible if you are interested in participating.